Navigation Links
Palatin Technologies, Inc. Receives $2.5 Million from AstraZeneca
Date:3/23/2010

CRANBURY, N.J., March 23 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) announced today that it received $2.5 million from AstraZeneca AB pursuant to the September 2009 amendment of the exclusive research collaboration and license agreement to discover, develop and commercialize compounds that target melanocortin receptors for treatment of obesity and related indications.

Payment of the $2.5 million was contingent on the successful completion by Palatin of certain tasks this quarter relating to the program.  Palatin received an initial $2.5 million upon signing the September 2009 amendment.

Separately, Palatin announced receipt of a letter from NYSE Amex determining that Palatin successfully resolved the continued listing deficiencies referenced in a December 2008 letter from NYSE Amex.  

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company dedicated to the development of peptide, peptide mimetic and small molecule agonists with a focus on melanocortin and natriuretic peptide receptor systems. Palatin's internally developed drug pipeline utilizes proprietary approaches to discover potent rigid conformers from flexible peptide starting points. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin Technologies' website at www.palatin.com.

SOURCE Palatin Technologies, Inc.

Back to top

RELATED LINKS
http://www.palatin.com

'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
2. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
3. Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994
4. Palatin Technologies Presents PL-3994 Clinical Trial Results at the 12th Annual Scientific Meeting of the Heart Failure Association of America
5. Palatin Technologies to Present at 8th Annual BIO Investor Forum
6. Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men
7. Palatin Technologies, Inc. To Raise $2.6 Million Dollars in Registered Direct Offering
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
10. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
11. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... March 28, 2017  Medeon Biodesign, Inc., a ... is pleased to announce that the Company led ... Panther Orthopedics, Inc., a San Jose, ... solutions for orthopedic extremity applications.  ... rapidly, primarily due to procedure volume growth, lifestyle ...
(Date:3/27/2017)... TEL-AVIV, Israel , March 27, 2017 /PRNewswire/ ... TASE: THXBY), a specialty clinical-stage pharmaceutical company specializing in the ... of its public offering in the ... Shares (ADSs), each ADS representing 40 ordinary shares ... per ADS. In addition, Therapix has granted the ...
(Date:3/27/2017)... STUTTGART, Germany , March 27, 2017 /PRNewswire/ ... provide over 7,000 attendees and more than 600 ... learn, and discover opportunities and solutions that will ... - 6 April 2017 at the Messe Stuttgart, ... is the preeminent medical technology platform showcasing the ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... Calibration, qualification, ... ensuring high-quality results and maintaining GMP and USP compliance. In a new webinar ... with GMP requirements " these requirements are explained. The challenge is to ...
(Date:3/28/2017)... ... 28, 2017 , ... Neurotechnology , a provider of ... attendance tracking products: the new NCheck Cloud Bio Attendance cloud-based service and the ... face recognition to enable users to check in and out from anywhere via ...
(Date:3/28/2017)... Appleton, WI (PRWEB) , ... March 28, 2017 ... ... how self-funded health plans work, the Self-Funding Success website has recently developed and ... about Self-Funded Health Plans ” was created based on common inquiries the site’s ...
(Date:3/28/2017)... ... , ... A minimally invasive porcelain veneer is increasing in ... of Dental Laboratories (NADL) is informing dentists about the benefits of minimally invasive ... laboratories and technicians that create these veneers. , According to National Board ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... Public relations ... and across a variety of business channels. , While many results are clear, much ... public relations program. , When it comes to measurement, firms should always take ...
Breaking Medicine News(10 mins):